Xenon Pharmaceuticals (XENE) BofA Securities CNS Therapeutics Virtual Conference 2024 summary

Strategic focus and pipeline overview

• Emphasis on azetukalner as a lead molecule for epilepsy and major depressive disorder, with three phase 3 trials in epilepsy and three planned in depression.

• Discovery pipeline maturing, with three key targets: Kv7, Nav1.1 (seizure disorders), and Nav1.7 (pain), and multiple molecules expected to enter clinical development in the next 1-2 years.

• Strong financial position with cash runway into 2027 to support late-stage programs.

• Transitioning toward a commercial organization with significant clinical data expected in 2025 and beyond.

Clinical data and product differentiation

• Azetukalner shows compelling efficacy in epilepsy, with best-in-class results for focal onset seizures and significant long-term seizure freedom rates.

• No titration required, rapid onset of efficacy, and no identified drug-drug interactions, differentiating it from competitors.

• Emerging mood benefit observed, potentially addressing comorbid depression in epilepsy patients.

• Phase 3 X-TOLL2 trial expected to read out in the second half of next year, critical for NDA filing.

Market opportunity and competitive landscape

• U.S. adult epilepsy market includes 3 million patients, with about half underserved by current therapies; focal onset seizures represent 60% of the market.

• Existing drugs lack mechanistic diversity, leading to unmet needs; azetukalner is the only product with clinical data in the Kv7 space.

• Ease of use and mood benefit position azetukalner as a potential first-choice branded therapy, especially compared to drugs like XCOPRI and Vimpat.